Monday, 11 September 2017

Now Comes the Hard Part at Teva

Investors love Teva’s new CEO, but falling generic drug prices and high debt will weigh on shares.

from WSJ.com: Markets http://ift.tt/2y0ZmbO
via https://ifttt.com/ IFTTT
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)